Meeting
2019 ASCO Annual Meeting
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Authors
Warren P. Mason
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Warren P. Mason , Santosh Kesari , Roger Stupp , Dawit Gebremichael Aregawi , David Eric Piccioni , Patrick Roth , Annick Desjardins , Steven D. Reich , Marie-Laure Casadebaig , Ileana Elias , Benjamin Winograd , Nancy Levin , Daniela Annenelie Bota
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02903069
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2021)
DOI
10.1200/JCO.2019.37.15_suppl.2021
Abstract #
2021
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.
First Author: Louis B. Nabors
Poster
2019 ASCO Annual Meeting
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
First Author: Patrick Roth
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu